Alecensa 150 MG capsule UU 240S
Ended Awarded Last action
- Contract number
- SPE2DR26FJPA1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,029
Award facts
- Contract value 100% obligated
- $28,028.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $28,028.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240 count). The award, issued on January 27, 2026, with an ultimate completion date of February 18, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group was selected under its single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to streamline pharmaceutical supply chains for Department of Defense military healthcare facilities worldwide.
As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group maintains a comprehensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's substantial federal contracting activity through the DLA's Medical Supply Chain division, combined with its established performance across multiple therapeutic categories, demonstrates its capability to fulfill the diverse pharmaceutical requirements of military healthcare operations. This delivery order represents one of numerous awards issued to the vendor, which holds a contract ceiling of $499,999,999 extending through December 31, 2036, positioning it as a key regional prime vendor within the broader PPV-G GEN V framework.
Quick answers
Who was awarded contract SPE2DR26FJPA1?
SPE2DR26FJPA1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FJPA1 worth?
The government has obligated $28,029 on SPE2DR26FJPA1.
Is contract SPE2DR26FJPA1 an order under another contract?
Yes. SPE2DR26FJPA1 is a delivery order under SPE2DR25D9226, an indefinite delivery contract.
Was contract SPE2DR26FJPA1 competed?
The extent of competition for SPE2DR26FJPA1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award